BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ang D, Koo SH, Chan YH, Tan TY, Soon GH, Tan CK, Lin KW, Krishnasamy-Balasubramanian JK, Wong YJ, Kumar R, R R, Tan Y, Ong PJ, Tan YJ, Li JW, Kwek AB, Ang TL. Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication. Aliment Pharmacol Ther 2022. [PMID: 35665947 DOI: 10.1111/apt.17070] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Ang D, Koo SH. Editorial: slow progress to optimising H. pylori eradication treatment with antisecretory drugs-authors' reply. Aliment Pharmacol Ther 2022;56:1076-7. [PMID: 35995742 DOI: 10.1111/apt.17167] [Reference Citation Analysis]
2 Gisbert JP, Hunt RH. Editorial: slow progress to optimising H. pylori eradication treatment with antisecretory drugs. Aliment Pharmacol Ther 2022;56:1074-5. [PMID: 35995738 DOI: 10.1111/apt.17142] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ang D. Letter: a promising Helicobacter pylori regimen-vonoprazan-based therapy. Author's reply. Aliment Pharmacol Ther 2022;56:754-5. [PMID: 35879904 DOI: 10.1111/apt.17133] [Reference Citation Analysis]
4 Hu Y, Lu NH. Letter: a promising Helicobacter pylori regimen - vonoprazan-based therapy. Aliment Pharmacol Ther 2022;56:752-3. [PMID: 35879899 DOI: 10.1111/apt.17114] [Reference Citation Analysis]